The WHO issued new guidelines endorsing GLP-1 receptor agonists for the long-term treatment of obesity in adults. GLP-1 drugs must be combined with counseling on behavioral and lifestyle changes, the ...

Add Yahoo as a preferred source to see more of our stories on Google. The World Health Organization (WHO) on Monday issued its first-ever global guidelines on the use of GLP-1 medications for treating ...

The World Health Organization (WHO) has recommended the use of GLP-1 medications as part of treatment programs to help people manage obesity. In a new guideline published in JAMA, WHO officials said ...

A new World Health Organization (WHO) guideline recommending GLP-1s for obesity treatment along with recent efforts to reduce the drugs’ costs are unlikely to change US obesity practice — but actions ...

Add Yahoo as a preferred source to see more of our stories on Google. The World Health Organization has laid down its first guidelines for GLP-1 drugs like Wegovy and Zepbound.

The World Health Organization on Monday issued its first guideline on the use of GLP-1 therapies for obesity, conditionally recommending them as part of long-term treatment for the condition, which ...

Jessica Rendall is a reporter with experience covering a variety of health and wellness topics, including chronic disease, ...

GLP-1 receptor agonists for obesity are effective over the long term when paired with lifestyle interventions, but global accessibility must be improved, the World Health Organization (WHO) concluded.

The World Health Organization (WHO) on Monday issued its first-ever global guidelines on the use of GLP-1 medications for treating obesity as a chronic illness. In a press release, the WHO said this ...

New guidelines from the World Health Organization (WHO) recommend using GLP-1 medications to help manage obesity. The agency said the weight-loss drugs should be used in conjunction with a healthy ...